EDMA

This article is about a substituted amphetamine. For other uses, see EDMA (disambiguation).
EDMA
Clinical data
Routes of
administration		 Oral
ATC code none
Legal status
Legal status
Identifiers
PubChem (CID) 24257269
ChemSpider 23553090 YesY
Chemical and physical data
Formula C12H17NO2
Molar mass 207.269 g/mol
3D model (Jmol) Interactive image
  (verify)


3,4-Ethylenedioxy-N-methylamphetamine (EDMA) is an entactogen drug of the amphetamine class.[1][2] It is an analogue of MDMA where the methylenedioxy ring has been replaced by an ethylenedioxy ring.[1][2] EDMA was first synthesized by Alexander Shulgin.[1] In his book PiHKAL, the dosage is listed as 150–250 mg, and the duration listed as 3–5 hours.[1] According to Shulgin, EDMA produces a bare threshold consisting of paresthesia, nystagmus, and hypnogogic imagery, with few to no other effects.[1] Scientific research has demonstrated that EDMA acts as a non-neurotoxic serotonin releasing agent with moderately diminished potency relative to MDMA, and with negligible effects on dopamine release.[2] Based on Shulgin's reports of essential inactivity at 150–250 mg, it may be more active at higher doses.

References

  1. 1 2 3 4 5 Ann Shulgin; Alexander Shulgin (1991). Pihkal: A Chemical Love Story. Transform Press. ISBN 0-9630096-0-5.
  2. 1 2 3 McKenna DJ, Guan XM, Shulgin AT (March 1991). "3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine". Pharmacology, Biochemistry, and Behavior. 38 (3): 505–12. doi:10.1016/0091-3057(91)90005-M. PMID 1829838.
This article is issued from Wikipedia - version of the 8/15/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.